Exagen Inc expected to post a loss of 26 cents a share - Earnings Preview

Exagen

07/03/2025 12:49

Exagen Inc XGN.OQ XGN.O is expected to show a rise in quarterly revenue when it reports  results on March 11 for the period ending December 31 2024

The Vista California-based  company is expected to report a 0.6% increase in revenue to $13.848 million from $13.77 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Exagen Inc is for a loss of 26 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Exagen Inc is $7.00‚Äč, above‚Äč its last closing price of $3.13. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.29
-0.29
-0.28
Beat
3.4
Jun. 30 2024
-0.34
-0.34
-0.16
Beat
53.6
Mar. 31 2024
-0.36
-0.36
-0.19
Beat
47.5‚Äč
Dec. 31 2023
-0.40
-0.43
-0.31
Beat
28.5
‚Äč‚ÄčSep. 30 2023
-0.46
-0.47
-0.31
Beat
34
Jun. 30 2023
-0.50
-0.49
-0.28
Beat
43.4‚Äč
Mar. 31 2023
-0.57
-0.56
-0.44
Beat
21.7
Dec. 31 2022
-0.81
-0.78
-0.83
Missed
-6.4

This summary was machine generated March 7 at 12:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)